← United States · Coverage record
US · SEC FORM 4
X4 Pharmaceuticals, Inc
XFOR · Nasdaq · CIK 0001501697 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
5 Form 4 transaction lines observed in the same window
5 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-10-23 · Craig Adam R.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 7,590,000
- Previous report
- 8,236,475
- Avg daily volume
- 1,256,869
- Days to cover
- 6.0
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-10-23 | Craig Adam R | Purchase (P) | Common Stock | 86,206 | USD 2.90 | USD 249,997 | SEC filing ↗ |
| 2025-05-16 | Baldry Mark | Purchase (P) | Common Stock | 1,032 | USD 2.48 | USD 2,559 | SEC filing ↗ |
| 2024-11-15 | Baldry Mark | Purchase (P) | Common Stock | 13,404 | USD 0.34 | USD 4,557 | SEC filing ↗ |
| 2024-05-17 | Baldry Mark | Purchase (P) | Common Stock | 21,646 | USD 0.68 | USD 14,719 | SEC filing ↗ |
| 2023-08-18 | WYZGA MICHAEL S | Purchase (P) | Common Stock | 25,000 | USD 1.20 | USD 30,000 | SEC filing ↗ |
Form 4 evidence
6 transaction lines in the latest 365-day window; 191 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | KIRSKE DAVID | Sale (S) | Common Stock | 11,767 | USD 2.86 | USD 33,658 | SEC filing ↗ |
| 2026-08-12 | Volpone John | Sale (S) | Common Stock | 24,576 | USD 4.44 | USD 109,117 | SEC filing ↗ |
| 2026-08-12 | Craig Adam R | Sale (S) | Common Stock | 47,436 | USD 4.44 | USD 210,616 | SEC filing ↗ |
Show recent Form 4 evidence (6 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | KIRSKE DAVID | Sale (S) | Common Stock | 11,767 | USD 2.86 | USD 33,658 | SEC filing ↗ |
| 2026-08-12 | Volpone John | Sale (S) | Common Stock | 24,576 | USD 4.44 | USD 109,117 | SEC filing ↗ |
| 2026-08-12 | Craig Adam R | Sale (S) | Common Stock | 47,436 | USD 4.44 | USD 210,616 | SEC filing ↗ |
| 2026-06-30 | KIRSKE DAVID | Sale (S) | Common Stock | 8,543 | USD 4.26 | USD 36,393 | SEC filing ↗ |
| 2026-05-12 | KIRSKE DAVID | Sale (S) | Common Stock | 16,961 | USD 4.29 | USD 72,763 | SEC filing ↗ |
| 2025-10-23 | Craig Adam R | Purchase (P) | Common Stock | 86,206 | USD 2.90 | USD 249,997 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | XFOR |
| CIK | 0001501697 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 191 transaction lines from 2020-03-02 to 2026-10-01 5 P purchase lines · 104 S sale lines · 82 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.